Literature DB >> 1419908

Protein prenylation: key to ras function and cancer intervention?

R Khosravi-Far1, A D Cox, K Kato, C J Der.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1419908

Source DB:  PubMed          Journal:  Cell Growth Differ        ISSN： 1044-9523


× No keyword cloud information.
  27 in total

1.  Production and Membrane Binding of N-Terminally Acetylated, C-Terminally Farnesylated and Carboxymethylated KRAS4b.

Authors:  Simon Messing; Constance Agamasu; Matt Drew; Caroline J DeHart; Andrew G Stephen; William K Gillette
Journal:  Methods Mol Biol       Date:  2021

2.  Statin use and risk of prostate cancer: results from a population-based epidemiologic study.

Authors:  Ilir Agalliu; Claudia A Salinas; Philip D Hansten; Elaine A Ostrander; Janet L Stanford
Journal:  Am J Epidemiol       Date:  2008-06-12       Impact factor: 4.897

3.  Identification of novel peptide substrates for protein farnesyltransferase reveals two substrate classes with distinct sequence selectivities.

Authors:  James L Hougland; Katherine A Hicks; Heather L Hartman; Rebekah A Kelly; Terry J Watt; Carol A Fierke
Journal:  J Mol Biol       Date:  2009-10-28       Impact factor: 5.469

4.  LKB1, a novel serine/threonine protein kinase and potential tumour suppressor, is phosphorylated by cAMP-dependent protein kinase (PKA) and prenylated in vivo.

Authors:  S P Collins; J L Reoma; D M Gamm; M D Uhler
Journal:  Biochem J       Date:  2000-02-01       Impact factor: 3.857

5.  Mediation of signal transduction in keratinocytes of human middle ear cholesteatoma by ras protein.

Authors:  C C Huang; C T Chen; T S Huang; H Shinoda
Journal:  Eur Arch Otorhinolaryngol       Date:  1996       Impact factor: 2.503

Review 6.  Aberrant function of the Ras signal transduction pathway in human breast cancer.

Authors:  G J Clark; C J Der
Journal:  Breast Cancer Res Treat       Date:  1995-07       Impact factor: 4.872

7.  Suppression in mevalonate synthesis mediates antitumor effects of combined statin and gamma-tocotrienol treatment.

Authors:  Vikram B Wali; Sunitha V Bachawal; Paul W Sylvester
Journal:  Lipids       Date:  2009-09-24       Impact factor: 1.880

8.  Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton.

Authors:  G C Prendergast; J P Davide; S J deSolms; E A Giuliani; S L Graham; J B Gibbs; A Oliff; N E Kohl
Journal:  Mol Cell Biol       Date:  1994-06       Impact factor: 4.272

Review 9.  Molecularly targeted therapies for pediatric acute myeloid leukemia: progress to date.

Authors:  Patrick Brown; Franklin O Smith
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

10.  Tipifarnib in the treatment of acute myeloid leukemia.

Authors:  Xavier Thomas; Mohamed Elhamri
Journal:  Biologics       Date:  2007-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.